Table 22:

Guidelines for Monitoring A-VEGF Treated n-AMD Patients

Society	Year of Recommendation	Guideline
American Academy of Ophthalmology (94)	2008	Follow-up exams (OCT, FA) to be performed as indicated depending on clinical findings and clinical judgment of treating ophthalmologists
International Council of Ophthalmology (95)	2011	After 0.5-mg ranibizumab intravitreal injections, return exam should be approximately 4 weeks after treatment; subsequent follow-up depends on clinical findings and judgment of treating ophthalmologist
Canadian Expert Consensus (24)	2012	Superior VA outcomes in the maintenance phase are achieved with monthly dosing; when not feasible, an individualized regimen with close monitoring by OCT is an option
Italian Retinal Expert Consensus (5)	2012	Use OCT before and after each loading dose, then 1 month after final load. Considering the practical difficulties of monthly monitoring, book monthly checks to 6 months and then every 2 months if no recurrence
European International Retinal Expert Panel (28)	2013	When monthly regimen is impossible, a flexible strategy with monthly monitoring is feasible, but VA benefits might be reduced. A flexible approach requires close monitoring to capture signs of active disease and to re-initiate treatment without delay. Where possible the monthly evaluation should include OCT, the most sensitive means of detecting VEGF-induced permeability changes

Abbreviations: FA, fluorescein angiography; OCT, optical coherence tomography; VA, visual acuity; VEGF, vascular endothelial growth factor.